India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide — are now available in the Indian market. Here’s how they work, how ...

A recent study reveals that nearly 20% of Indian households have all adults classified as overweight, while 10% are obese.

Abdominal obesity, based on Indian guidelines, means a waist over 90cm (35 inches) for men and 80cm (31 inches) for women. Among women aged 30 to 49, nearly one in two already show signs of it.

With the launch of Wegovy by Danish pharmaceutical giant Novo Nordisk and US major Eli Lilly’s Mounjaro already in ...

According to a study in The Lancet, over 14.4 million children in India are obese, making the country home to the ...

Kombucha's popularity in India grows, but scientific evidence lags; new study explores gut microbiome effects for health.

Abdominal obesity, based on Indian guidelines, means a waist over 90cm (35 inches) for men and 80cm (31 inches) for women. Among women aged 30 to 49, nearly one in two already show signs of it.

The drug works by acting on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, ...

Eli Lilly receives approval for Mounjaro in prefilled Kwikpen as competition intensifies in India's weight-loss drug market ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...